Tammam Obeid1, Isibor Arhuidese1, Alicia Gaidry1, Umair Qazi1, Christopher Abularrage1, Philip Goodney2, Jack Cronenwett2, Mahmoud Malas3. 1. Division of Vascular and Endovascular Therapy, Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Md. 2. Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH. 3. Division of Vascular and Endovascular Therapy, Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Md. Electronic address: bmalas1@jhmi.edu.
Abstract
BACKGROUND: Proper selection of patients for carotid artery stenting (CAS) remains controversial despite multiple controlled trials. This relates in part to differences in interpretation of the relative importance of myocardial vs stroke complications after the procedure by different specialties and a lack of granular clinical data to analyze outcomes outside the large clinical trials. The objective of this study was to assess the effect of preoperative medications, procedure parameters, and patient characteristics on outcomes of CAS performed in a multispecialty national database. METHODS: We analyzed all patients who underwent CAS between 2005 and 2014 in the Vascular Quality Initiative. A multivariate logistic regression model was built to assess the effects of age, gender, comorbidities, smoking, preprocedure medications, procedure details, and hypotension or hypertension that required intravenous medication on 30-day death or stroke rates. RESULTS: A total of 5263 patients underwent CAS (mean age, 70 years; 63% male). The 30-day stroke/death rate was 3.4% (1.5% minor stroke, 0.9% major stroke, and 1.2% death; 40% of patients who had major strokes died within 30 days), and the myocardial infarction rate was 0.8%. Postprocedural hypertension requiring treatment occurred in 519 cases (9.9%), and it was associated with a 3.4-fold increase in stroke/death (odds ratio, 3.39; 95% confidence interval, 2.30-5.00; P < .0001). Preprocedural beta-blocker use for >30 days was associated with a 34% reduction in the stroke/death risk (odds ratio, 0.66; 95% confidence interval, 0.46-0.95; P = .025) compared with nonuse. Beta-blocker use was not associated with postprocedural hypotension. Other predictors of postoperative stroke and death included age, symptomatic status, diabetes (type 1 or type 2), and postprocedural hypotension, whereas prior carotid endarterectomy and distal embolic protection use were protective. CONCLUSIONS: Postprocedural hypertension and hypotension that require treatment are both strongly associated with periprocedural stroke/death after CAS. Beta blockers significantly reduce the stroke/death risk associated with carotid stenting and should be investigated prospectively for potential use during CAS.
BACKGROUND: Proper selection of patients for carotid artery stenting (CAS) remains controversial despite multiple controlled trials. This relates in part to differences in interpretation of the relative importance of myocardial vs stroke complications after the procedure by different specialties and a lack of granular clinical data to analyze outcomes outside the large clinical trials. The objective of this study was to assess the effect of preoperative medications, procedure parameters, and patient characteristics on outcomes of CAS performed in a multispecialty national database. METHODS: We analyzed all patients who underwent CAS between 2005 and 2014 in the Vascular Quality Initiative. A multivariate logistic regression model was built to assess the effects of age, gender, comorbidities, smoking, preprocedure medications, procedure details, and hypotension or hypertension that required intravenous medication on 30-day death or stroke rates. RESULTS: A total of 5263 patients underwent CAS (mean age, 70 years; 63% male). The 30-day stroke/death rate was 3.4% (1.5% minor stroke, 0.9% major stroke, and 1.2% death; 40% of patients who had major strokes died within 30 days), and the myocardial infarction rate was 0.8%. Postprocedural hypertension requiring treatment occurred in 519 cases (9.9%), and it was associated with a 3.4-fold increase in stroke/death (odds ratio, 3.39; 95% confidence interval, 2.30-5.00; P < .0001). Preprocedural beta-blocker use for >30 days was associated with a 34% reduction in the stroke/death risk (odds ratio, 0.66; 95% confidence interval, 0.46-0.95; P = .025) compared with nonuse. Beta-blocker use was not associated with postprocedural hypotension. Other predictors of postoperative stroke and death included age, symptomatic status, diabetes (type 1 or type 2), and postprocedural hypotension, whereas prior carotid endarterectomy and distal embolic protection use were protective. CONCLUSIONS: Postprocedural hypertension and hypotension that require treatment are both strongly associated with periprocedural stroke/death after CAS. Beta blockers significantly reduce the stroke/death risk associated with carotid stenting and should be investigated prospectively for potential use during CAS.
Authors: John J Ricotta; Ali Aburahma; Enrico Ascher; Mark Eskandari; Peter Faries; Brajesh K Lal Journal: J Vasc Surg Date: 2011-09 Impact factor: 4.268
Authors: Thompson G Robinson; Suzanne L Dawson; Penelope J Eames; Ronney B Panerai; John F Potter Journal: Stroke Date: 2003-02-27 Impact factor: 7.914
Authors: Andreas Kastrup; Klaus Gröschel; Hilmar Krapf; Bernhard R Brehm; Johannes Dichgans; Jörg B Schulz Journal: Stroke Date: 2003-02-13 Impact factor: 7.914
Authors: Robert W Hobson; Virginia J Howard; Gary S Roubin; Thomas G Brott; Robert D Ferguson; Jeffrey J Popma; Darlene L Graham; George Howard Journal: J Vasc Surg Date: 2004-12 Impact factor: 4.268
Authors: Bernhard Reimers; Michael Schlüter; Fausto Castriota; Thilo Tübler; Nicola Corvaja; Carlo Cernetti; Raffaella Manetti; Amedeo Picciolo; Francesco Liistro; Carlo Di Mario; Alberto Cremonesi; Joachim Schofer; Antonio Colombo Journal: Am J Med Date: 2004-02-15 Impact factor: 4.965
Authors: Isibor J. Arhuidese; Muhammad Faateh; Besma J. Nejim; Satinderjit Locham; Christopher J. Abularrage; Mahmoud B. Malas Journal: JAMA Surg Date: 2018-03-01 Impact factor: 14.766
Authors: Michiel H F Poorthuis; Reinier A R Herings; Kirsten Dansey; Johanna A A Damen; Jacoba P Greving; Marc L Schermerhorn; Gert J de Borst Journal: Stroke Date: 2021-10-12 Impact factor: 7.914
Authors: Nadin Elsayed; Jonathan Unkart; Mohammad Abdelgawwad; Isaac Naazie; Peter F Lawrence; Mahmoud B Malas Journal: J Am Heart Assoc Date: 2022-08-24 Impact factor: 6.106
Authors: P Nazari; P Golnari; M C Hurley; A Shaibani; S A Ansari; M B Potts; B S Jahromi Journal: AJNR Am J Neuroradiol Date: 2021-04-01 Impact factor: 4.966